Bicycle Therapeutics (BCYC)
NASDAQ: BCYC
· Real-Time Price · USD
7.10
0.13 (1.87%)
At close: Sep 05, 2025, 12:56 PM
1.87% (1D)
| Bid | 7.1 |
| Market Cap | 491.7M |
| Revenue (ttm) | 19.28M |
| Net Income (ttm) | -242.36M |
| EPS (ttm) | -3.52 |
| PE Ratio (ttm) | -2.02 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 7.12 |
| Volume | 53,728 |
| Avg. Volume (20D) | 278,011 |
| Open | 7.05 |
| Previous Close | 6.97 |
| Day's Range | 6.98 - 7.23 |
| 52-Week Range | 6.10 - 28.67 |
| Beta | 1.45 |
About BCYC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCYC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCYC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Bicycle Therapeutics is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+13.9%
Bicycle Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 weeks ago · fool.com
Bicycle (BCYC) Q2 Revenue Falls 69%Bicycle (BCYC) Q2 Revenue Falls 69%
2 months ago · businesswire.com
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to e...